0.2086
price down icon3.47%   -0.0075
after-market Dopo l'orario di chiusura: .20 -0.0086 -4.12%
loading
Precedente Chiudi:
$0.2161
Aprire:
$0.23
Volume 24 ore:
1.21M
Relative Volume:
0.89
Capitalizzazione di mercato:
$18.18M
Reddito:
-
Utile/perdita netta:
$-26.92M
Rapporto P/E:
-0.409
EPS:
-0.51
Flusso di cassa netto:
$-18.92M
1 W Prestazione:
-9.46%
1M Prestazione:
-39.83%
6M Prestazione:
-80.69%
1 anno Prestazione:
-88.21%
Intervallo 1D:
Value
$0.1912
$0.23
Intervallo di 1 settimana:
Value
$0.1814
$0.2364
Portata 52W:
Value
$0.1814
$2.39

Cel-Sci Corp. Stock (CVM) Company Profile

Name
Nome
Cel-Sci Corp.
Name
Telefono
703-506-9460
Name
Indirizzo
8229 Boone Boulevard, Suite 802, Vienna, VA
Name
Dipendente
0
Name
Cinguettio
@CelSciCorp
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
CVM's Discussions on Twitter

Confronta CVM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CVM
Cel-Sci Corp.
0.2086 18.18M 0 -26.92M -18.92M -0.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 32.85B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 28.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-01-13 Iniziato H.C. Wainwright Buy
2015-03-02 Iniziato Dawson James Buy

Cel-Sci Corp. Borsa (CVM) Ultime notizie

pulisher
Apr 06, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World

Apr 06, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025
pulisher
Mar 29, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025
pulisher
Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance

Mar 17, 2025
pulisher
Mar 15, 2025

Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register

Mar 15, 2025
pulisher
Mar 14, 2025

Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan

Mar 14, 2025
pulisher
Mar 13, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 05, 2025

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

Mar 05, 2025
pulisher
Mar 05, 2025

CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL

Mar 05, 2025
pulisher
Feb 28, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace

Feb 19, 2025
pulisher
Feb 18, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter

Feb 18, 2025
pulisher
Feb 18, 2025

Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - Stock Titan

Feb 18, 2025
pulisher
Feb 17, 2025

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA

Feb 15, 2025
pulisher
Feb 14, 2025

Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 10, 2025

CVM: Fiscal Year 2024 Results - Research Tree

Feb 10, 2025
pulisher
Feb 03, 2025

LD Micro 360 Companies Set to Present this Week - ACCESS Newswire

Feb 03, 2025
pulisher
Jan 27, 2025

Personal Finance - Business Wire

Jan 27, 2025
pulisher
Jan 21, 2025

Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

Have A Relaxing Holiday Season - MENAFN.COM

Jan 20, 2025
pulisher
Jan 18, 2025

Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World

Jan 18, 2025
pulisher
Jan 14, 2025

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews

Jan 13, 2025

Cel-Sci Corp. Azioni (CVM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Capitalizzazione:     |  Volume (24 ore):